Founded with the mission to revolutionize drug discovery, Mirimus specializes in developing preclinical RNA interference (RNAi) animal models that predict the toxicities of potential drug therapies without using the actual drugs. Their core vision is to enhance the drug discovery process by providing superior predictive models. Mirimus offers a range of preclinical services, including advanced genetically engineered in vivo models and cutting-edge gene editing technologies, focusing on scalable solutions for evaluating novel therapeutic targets.
Notably, Mirimus has received recognition as an XPRIZE award-winning biotech company. Their innovative approach has garnered attention from key investors and industry leaders. The company’s significant achievements include pioneering advancements in human health through high-quality animal and cell models, which have had a substantial impact on the field of drug discovery and development.
